Home | Welcome to Contract Pharma   
Last Updated Tuesday, June 2 2015

Print

Search Results for 'Collaborations'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published June 2, 2015
Will evaluate investigational candidates in cancer patients Read More »
Published June 1, 2015
Will focus on exploring potential combinations of PS-targeting agents Read More »
Published May 29, 2015
Will utilize NanoString’s nCounter Analysis to optimize gene expression signatures Read More »
Published May 29, 2015
Will evaluate AZ’s investigational anti-PD-L1 with Lilly’s CYRAMZA Read More »
Published May 27, 2015
Believes events of suicidal ideation and behavior likely to restrict labeling Read More »
Published May 21, 2015
Biomay to apply VTU Pichia strains for the production of recombinant allergens Read More »
Published May 20, 2015
Will use Achillion assets to develop pan-genotypic oral regimen for HCV Read More »
Published May 19, 2015
Will evaluate combinations of Advaxis’s Lm-LLO immunotherapy technology and Sorrento’s immunomodulatory antibodies Read More »
Published May 18, 2015
Increases funds for R&D efforts for Structured Organic Particulate Systems Read More »
Published May 18, 2015
Phase I drug demonstrates oral bioavailability, target inhibition, safety and tolerability Read More »
Published May 18, 2015
Aims to target underlying causes of MS disease progression Read More »
Published May 14, 2015
Will combine biotech capabilities to develop therapies for autoimmune disorders Read More »
Published May 13, 2015
Group initiates a prime boost study of Ebola vaccine candidates Read More »
Published May 12, 2015
Will collaborate to identify and validate tumor targets and corresponding TCRs in cancer Read More »
Published May 11, 2015
Firms will co-develop Elasmogen's soloMER technology Read More »
Published May 7, 2015
Will combine biotech capabilities to develop therapies for autoimmune disorders Read More »
Published May 7, 2015
Combines two next-gen discovery platforms Read More »
Published May 1, 2015
Validates undisclosed target to treat a neurological disorder Read More »
Published April 23, 2015
Initiates Phase III Trial Read More »
Published April 20, 2015
Will evaluate birinapant in combination with KEYTRUDA in solid tumors Read More »
Published April 16, 2015
Will conduct combination trails in melanoma Read More »
Published April 15, 2015
Will provide discovery and development services from gene to candidates and beyond Read More »
Published April 15, 2015
Alliance expanded to include select pre-commercialization activities Read More »
Published April 15, 2015
Plans to progress development candidate through IND-enabling studies Read More »
Published April 13, 2015
Diversifies development risk with second, complementary acute pain product Read More »
Published April 10, 2015
Aims to improve clinical research Read More »
Published April 7, 2015
Will roll-out in two waves Read More »
Published April 7, 2015
Enter into license agreement on novel small molecules targeting mTORC1 activation Read More »
Published April 7, 2015
Multi-year collaboration will focus on multiple disease targets across several therapeutic areas Read More »
Published April 6, 2015
Gains access to uniQure’s gene therapy technology platform for multiple targets Read More »
Published April 6, 2015
Aims to optimize two of Pfizer’s targeted oncology drugs Read More »
Published April 2, 2015
Partners with Shanghai Sine Promod Pharmaceutical to launch its new Budesonide DPI in China Read More »
Published April 1, 2015
£112,291 grant is awarded under Innovate UK’s Technology Inspired Innovation competition Read More »
Published April 1, 2015
Investment by ICF is its first in a US pharma company Read More »
Published April 1, 2015
Asubio's projects will be integrated into the Daiichi Sankyo's global development organization Read More »
Published March 30, 2015
Merck Serono gains access to Intrexon's suite of technologies to engineer T-cells Read More »
Published March 27, 2015
Will use RXi's self-delivering RNAi technology to develop cell-based immunotherapies to treat cancer Read More »
Published March 25, 2015
Will receive as much as £652,000 to expand bioproduction research Read More »
Published March 23, 2015
To develop Confluence’s lead candidate for Fragile X Syndrome Read More »
Published March 19, 2015
To develop and commercialize a portfolio of anti-tau antibodies Read More »
Published March 19, 2015
Phase II study will evaluate the safety and pharmacokinetics of Translarna in MPS I Read More »
Published March 19, 2015
To develop and commercialize Hanmi's oral BTK inhibitor Read More »
Published March 17, 2015
Collaboration will evaluate the combination of varlilumab and MPDL3280A Read More »
Published March 16, 2015
To discover and develop anti-cancer immunotherapies Read More »
Published March 13, 2015
Collaboration related to microbiome discovery and development Read More »
Published March 12, 2015
CL-108 demonstrates comparable bioavailability in pain indication Read More »
Published March 9, 2015
Opexa receives $3 million payment to support ongoing Phase IIb Abili-T trial Read More »
Published March 6, 2015
Advances Phase III Evaluation of SMNRx Read More »
Published March 5, 2015
To provide integrated offering for candidate selection through to early stage trials Read More »
Published March 5, 2015
Will evaluate pembrolizumab, lenvatinib and eribulin in Phase Ib/II trials Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On